-
Product Insights
NewNet Present Value Model: Johnson & Johnson’s PN-235
Empower your strategies with our Net Present Value Model: Johnson & Johnson's PN-235 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Protagonist Therapeutics Inc’s PN-235
Empower your strategies with our Net Present Value Model: Protagonist Therapeutics Inc's PN-235 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.Drug Operating Profit Model
-
Product Insights
NewLikelihood of Approval Analysis for Prurigo
Overview How likely is it that the drugs in Prurigo will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Prurigo Overview Prurigo nodularis (PN) is a skin disease characterized by pruritic (itchy)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gamma-PN in Streptococcal Pneumonia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gamma-PN in Streptococcal Pneumonia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Gamma-PN in Streptococcal Pneumonia Drug Details: Gamma-PN vaccine is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mirdametinib in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mirdametinib in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mirdametinib in Non-Small Cell Lung Cancer Drug Details: mirdametinib (PD-0325901)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mirdametinib in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mirdametinib in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mirdametinib in Ovarian Cancer Drug Details: mirdametinib (PD-0325901) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mirdametinib in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mirdametinib in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mirdametinib in Pancreatic Cancer Drug Details: mirdametinib (PD-0325901) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mirdametinib in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mirdametinib in Endometrial Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mirdametinib in Endometrial Cancer Drug Details: mirdametinib (PD-0325901) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mirdametinib in Thyroid Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mirdametinib in Thyroid Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mirdametinib in Thyroid Cancer Drug Details: mirdametinib (PD-0325901) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mirdametinib in Low-Grade Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mirdametinib in Low-Grade Glioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mirdametinib in Low-Grade Glioma Drug Details: mirdametinib (PD-0325901) is under development for...